Entera Bio (NASDAQ:ENTX) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Entera Bio (NASDAQ:ENTX) posted its quarterly earnings data on Friday. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02, Zacks reports. The company had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.04 million.

Entera Bio Price Performance

ENTX stock opened at $1.75 on Friday. The firm has a market cap of $62.62 million, a price-to-earnings ratio of -6.73 and a beta of 1.62. Entera Bio has a 1-year low of $1.41 and a 1-year high of $3.35. The firm has a fifty day moving average price of $2.14 and a two-hundred day moving average price of $2.02.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Entera Bio in a research note on Tuesday, March 18th.

Entera Bio Company Profile

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.